A clinical study to assess the time to initiation of biologic disease-modifying anti-rheumatic drugs (bDMARDs) in ESPOIR, the French cohort of patients with rheumatoid arthritis (RA), and factors associated with the timing of iologic Disease-modifying Antirheumatic Drug (bDMARD) initiation
Latest Information Update: 26 Jul 2021
At a glance
- Drugs Adalimumab (Primary) ; Etanercept (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
Most Recent Events
- 26 Jul 2021 New trial record